XML 67 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 140,734 $ 235,309 $ 176,319
License Revenue [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 22,590 116,434 14,323
Development Revenue [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 24,189 70,275 80,592
Development Revenue [Member] | Europe [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 9,624 21,679 17,954
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 0 14,323
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 22,590 108,434 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 284 248 1,220
AstraZeneca Agreements [Member] | China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 0 (90)
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 12,519 $ 48,345 $ 61,508